Iterum Therapeutics PLC (ITRM) — 8-K Filings

8-K Filings (32)

• 8-K Filing — Mar 31, 2026
• 8-K Filing — Dec 12, 2025
• Iterum Therapeutics Files 8-K — Oct 16, 2025 Risk: low
  On October 16, 2025, Iterum Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No speci
• Iterum Therapeutics Files 8-K on Security Holder Vote — Sep 10, 2025 Risk: low
  Iterum Therapeutics plc filed an 8-K on September 10, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specif
• Iterum Therapeutics Faces Delisting Concerns — Aug 28, 2025 Risk: high
  Iterum Therapeutics plc filed an 8-K on August 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event repo
• Iterum Therapeutics plc Files 8-K — Aug 20, 2025 Risk: low
  Iterum Therapeutics plc filed an 8-K on August 20, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, othe
• Iterum Therapeutics Files 8-K on Financials — Aug 5, 2025 Risk: low
  Iterum Therapeutics plc filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition, and including financial statements and e
• Iterum Therapeutics Enters Material Definitive Agreement — Aug 4, 2025 Risk: medium
  On July 29, 2025, Iterum Therapeutics plc entered into a material definitive agreement. The company, incorporated in Ireland with its principal executive office
• Iterum Therapeutics Sells Irish Subsidiary for $10M — Jul 18, 2025 Risk: medium
  Iterum Therapeutics plc announced on July 17, 2025, that it has entered into a definitive agreement to sell its subsidiary, Iterum Therapeutics Ireland Limited,
• Iterum Therapeutics Enters Material Definitive Agreement — Jun 11, 2025 Risk: medium
  On June 6, 2025, Iterum Therapeutics plc entered into a material definitive agreement. The filing does not provide specific details about the agreement, such as
• Iterum Therapeutics Enters Material Definitive Agreement — May 19, 2025 Risk: medium
  On May 13, 2025, Iterum Therapeutics plc entered into a material definitive agreement, likely related to financing or a significant business transaction. This f
• Iterum Therapeutics Files 8-K with Material Agreement — Apr 30, 2025 Risk: medium
  On April 28, 2025, Iterum Therapeutics plc entered into a material definitive agreement. The company also reported other events and filed financial statements a
• Iterum Therapeutics Announces Board and Executive Changes — Mar 10, 2025 Risk: medium
  Iterum Therapeutics plc announced on March 7, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure
• Iterum Therapeutics Files 8-K on Delisting and Board Changes — Feb 14, 2025 Risk: high
  Iterum Therapeutics plc filed an 8-K on February 14, 2025, reporting a notice of delisting or failure to satisfy continued listing rules, and changes in directo
• Iterum Therapeutics Completes Merger, Renamed Elicit Therapeutics — Dec 11, 2024 Risk: medium
  On December 10, 2024, Iterum Therapeutics plc filed an 8-K report detailing the completion of its previously announced business combination with Elicit Therapeu
• EQT to Acquire Iterum Therapeutics plc — Nov 21, 2024 Risk: medium
  Iterum Therapeutics plc announced on November 20, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of EQT AB. The transactio
• Iterum Therapeutics Secures $25M Loan Facility — Nov 1, 2024 Risk: medium
  On October 28, 2024, Iterum Therapeutics plc entered into a Loan Agreement with AOP Orphan Pharmaceuticals GmbH for a principal amount of $25.0 million. This ag
• Iterum Therapeutics Files 8-K with Financial Exhibits — Oct 25, 2024 Risk: low
  On October 25, 2024, Iterum Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates
• Iterum Therapeutics Faces Delisting Concerns — Oct 15, 2024 Risk: high
  Iterum Therapeutics plc filed an 8-K on October 15, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event rep
• Iterum Therapeutics Files 8-K on Shareholder Votes — Oct 8, 2024 Risk: low
  Iterum Therapeutics plc filed an 8-K on October 8, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific
• Iterum Therapeutics Faces Nasdaq Delisting Warning — Oct 4, 2024 Risk: medium
  Iterum Therapeutics plc announced on October 1, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules due to
• Iterum Therapeutics Files 8-K Report — Aug 6, 2024 Risk: low
  On August 6, 2024, Iterum Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating
• Iterum Therapeutics Files 8-K — Jul 22, 2024 Risk: low
  On July 22, 2024, Iterum Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rath
• Iterum Therapeutics Files 8-K Report — Jun 26, 2024 Risk: low
  On June 26, 2024, Iterum Therapeutics plc filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial tran
• Iterum Therapeutics Files 8-K on Shareholder Vote Matters — Jun 21, 2024 Risk: medium
  On June 19, 2024, Iterum Therapeutics plc filed an 8-K report detailing the submission of matters to a vote of security holders. The filing also includes other
• Iterum Therapeutics CMO Departs; Filings Made — May 31, 2024 Risk: medium
  Iterum Therapeutics plc announced on May 29, 2024, the departure of its Chief Medical Officer, Dr. Corey Fishman. The company also reported on compensatory arra
• Iterum Therapeutics Announces Board and Executive Changes — May 10, 2024 Risk: medium
  On May 10, 2024, Iterum Therapeutics plc filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the de
• Iterum Therapeutics Files 8-K — Apr 29, 2024 Risk: low
  On April 29, 2024, Iterum Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no other specific events o
• Iterum Therapeutics Faces Delisting Concerns — Apr 5, 2024 Risk: high
  Iterum Therapeutics plc filed an 8-K on April 5, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company's
• Iterum Therapeutics Files 8-K on Financials — Mar 29, 2024 Risk: medium
  Iterum Therapeutics plc filed an 8-K on March 29, 2024, reporting on its results of operations and financial condition as of March 28, 2024. The filing includes
• Iterum Therapeutics Files 8-K — Mar 6, 2024 Risk: low
  Iterum Therapeutics plc filed an 8-K on March 6, 2024, to report other events and financial statements. The filing does not contain specific details on new even
• Iterum Therapeutics Updates Address, Confirms Nasdaq Listing — Jan 30, 2024
  Iterum Therapeutics plc filed an 8-K on January 30, 2024, to update its registration information, specifically changing its address to Fitzwilliam Court, 1st Fl

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX